This modest or non-association between changes in post-treatment PSA level and therapy response or disease recurrence highlights a critical unmet need in PCa management—the need for more reliable and accurate indicators of patient status, namely therapy response or disease recurrence. This evidence concerns the gene KLK3 and posterior cortical atrophy.